The era of antibiotic therapy, now in its seventh decade, has dramatically reduced morbidity and mortality from infectious diseases. Through direct killing (bactericidal) or growth-limiting (bacteriostatic) activities, antibiotics are designed to cure conditions wherein bacteria have bypassed host immunity to establish clinically significant infection. As soluble mediators of innate defense, cationic antimicrobial peptides (AMPs) are "natural antibiotics" produced by epithelial surfaces and leukocytes that play a crucial role in restricting microbial proliferation to skin and mucosal surfaces (1) . The cathelicidin family of AMPs is represented by a single member in the mouse (mCRAMP) and humans (LL-37). Mice lacking mCRAMP are more susceptible to invasive bacterial infection of the skin or gastrointestinal tract (2, 3) , and differential levels of LL-37 production in skin lesions of atopic dermatitis (low) vs. psoriasis (high) correlate inversely with the susceptibility of human patients to bacterial superinfection (4) .
We sought to examine how pharmaceutical antibiotics might cooperate with AMPs in bacterial killing.
Unexpected results were observed when bacteria were simultaneously exposed to antibiotics with bacteriostatic properties and the innate defense peptides. In essence, certain drugs may be functioning at odds with our immune system rather than in synergy to achieve bacterial killing. Our findings reveal new avenues for investigation of the mechanism of action of key effectors of innate immunity and reinforce caution against the indiscriminate use of certain classes of antibiotics.
MATERIALS AND METHODS

Antibiotics, AMPs, serum, and wound fluid sources
Cell culture tested chloramphenicol (Cm) and erythromycin (Em) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Trimethoprim/sulfamethoxazole (TMP/SFX) was obtained from Elkins-Sinn Inc. (Cherry Hill, NJ, USA). LL-37 and mCRAMP were synthesized and purified (Ͼ99%) by the Louisiana State University Protein Facility. Piscidin/moronecidin was isolated from hybrid striped bass as described previously (5) . Normal human sera were collected from healthy donors. Human C9-deficient sera and C9 were obtained from Quidel (San Diego, CA, USA); 60 g/ml C9 were used for supplementation. Human surgical wound fluid was obtained from the University of California, San Diego (UCSD) Medical Center. Batches of mCRAMP and human serum with varying antimicrobial activity were used; thus, baseline concentrations used varied slightly in different experimental series. (6) , and its random Tn917 insertion mutant express-ing Em resistance were propagated in Todd-Hewitt broth (THB) media. Broad host range expression plasmid pDCerm (7) conferring Em resistance was introduced into S. aureus by electroporation. Cm-resistant E. coli ATCC 37535 was generated by passaging on THB agar with stepwise increasing concentrations of Cm (2 to Ͼ40 mg/ml). Unless otherwise noted, bacteria were grown overnight in THB without shaking and pelleted and washed twice for 3 min at 3200 g in the stated buffers and adjusted to the desired concentration by spectrophotometry confirmed by enumeration of colonyforming units (CFU).
Bacterial strains and growth conditions
AMP and complement-mediated killing assays
The bacterial WT strains and the Em-resistant S. aureus Tn917 mutant were grown overnight in THB; S. aureus ϩ pDCerm and Cm-resistant E. coli were grown in THB ϩ Em 50 g/ml or Cm 25 g/ml, respectively. For AMP killing assays, bacteria were washed twice in PBS or 20 mM phosphate buffer ϩ 1 mM MgCl 2 (PB) ϩ 1% THB for K. pneumoniae and E. coli or 10% THB for S. aureus. Subsequently, bacteria were incubated at 1 ϫ 10 7 CFU/ml in PB ϩ the above concentration of THB Ϯ the stated concentration of AMP Ϯ the stated concentration of Cm, Em, or TMP/SFX. For complement killing assays, overnight cultures of E. coli and K. pneumonia were washed twice in pyrogen-free RPMI 1640, 1% THB (RPMI-THB) Ϯ 5 g/ml Cm for E. coli or Ϯ 7 g/ml Cm for K. pneumoniae and adjusted to 1 ϫ 10 6 CFU/ml in RPMI-THB Ϯ the stated concentration of serum Ϯ the stated concentration of Cm or Em. For both AMP and complement killing assays, the bacteria were incubated in a total volume of 50 -200 l in individual wells of cell culture tested 96-well microtiterplates shaken on a rotator at 37°C and 200 rpm. Samples were drawn at various time points. Serial dilutions were plated to enumerate CFU.
Measurement and manipulation of S. aureus membrane potential
S. aureus was grown overnight in THB, washed twice with PBS, and incubated at 1 ϫ 10 7 CFU/ml in 200 l PB, 10% THB Ϯ 25 g/ml Cm in 96-well microtiter plates shaken at 37°C. For some experiments, the potassium ionophor valinomycin (100 M in 1% DMSO) was added at a final concentration of 5 M. Since 0.05% DMSO was present in the final valinomycintreated samples, control wells with 0.05% DMSO without valinomycin were included. After 30 min, samples were assayed using the BacLight bacterial membrane potential kit (Molecular Probes, Eugene, OR, USA) that uses 30 M carbocyanine dye 3,3Ј-diethyloxacarbocyanine iodide (DiOC 3 ) per manufacturer's instructions. DiOC 3 exhibits green fluorescence in all bacterial cells, shifting toward red emission when larger membrane potentials cause the dye to selfassociate. After being stained for 15 min, bacteria were analyzed by flow cytometry. Forward and side scatters were adjusted with logarithmic (log) signal amplification using a gate set on unstained bacteria. Subsequently, the log green and red fluorescence intensities of 15,000 stained bacterial particles per sample were measured after excitation with a 488 nm laser, and the ratio of red to green mean fluorescence intensity (MFI) was calculated as a size-independent indicator of membrane potential. For each sample, control bacteria were treated with propidium iodide (PI) at 50 g/ml to determine if Cm affected bacterial viability. PI was excited at 488 nm, and its fluorescence was measured above 600 nm; MFI was determined for 15,000 particles, and the ratio of red fluorescence to particle size (FSC-H) was calculated.
Confocal imaging of peptide binding to E. coli membranes
Bacteria in logarithmic phase (E. coli, OD 590 ϭ0.25) were grown Ϯ 3 g/ml Cm for 30 min and then incubated for 20 min at room temperature with rhodamine-labeled LL-37 peptide (25 M). Bacteria were then washed twice with PBS. Heat-killed bacteria (45 min; 55°C) served as a control to exclude peptide/antibiotic interaction. Binding of labeled peptide to E. coli membrane was determined by Olympus IX70 FV500 confocal laser-scanning microscopy at 12-bit resolution. Rhodamine excitation was set at 543 nm, and fluorescence was recorded from 505-525 nm.
Complement consumption assays
Antibody (Ab)-sensitized sheep erythrocytes (Sigma-Aldrich) were washed three times in gelatin veronal buffer (GVB 2ϩ ; Sigma-Aldrich) and placed on ice until use. E. coli was heat inactivated at 56°C for 60 min, washed twice in RPMI-THB, and adjusted to the desired concentration using a Neubauerimproved counting chamber for bacteria; 500 l RPMI-THB, 5% normal human serum (NHS) Ϯ 5 g/ml Cm were incubated with 0 to 2.5 ϫ 10 8 heat-inactivated E. coli cells/ml in sterile microreaction tubes using an overhead rotator. After 30 min of complement activation at 37°C, the bacteria were removed by centrifugation and the supernatants were placed on ice. The supernatants were diluted 1.6-fold in RPMI-THB and subsequently 1:5 into GVB 2ϩ containing 5 ϫ 10 7 Ab sensitized sheep erythrocytes/ml. Samples of 100 l were incubated in round bottom 96-well microtiter plates at 37°C with gentle shaking on a rotator. After 30 min, the plates were centrifuged at 1000 g for 5 min and the supernatants were diluted 1:5 into double-distilled H 2 0. Subsequently, the optical density (OD) was measured at 405 nm, the absorption maximum of hemoglobin (Hb). The data are shown in percent lysis; 100% lysis was achieved by diluting sheep erythrocytes 1:5 into double-distilled H 2 0.
Whole blood killing assays
Blood was drawn from healthy volunteers and heparinized. K. pneumoniae and E. coli were grown overnight as described above; the AMP-susceptible S. aureus dltA mutant was grown to the exponential growth phase in THB. Subsequently, bacteria were centrifuged and washed twice in PBS Ϯ 5 g/ml Cm for E. coli and K. pneumoniae and in PBS Ϯ 25 g/ml Cm for S. aureus; 800 l blood and 100 l bacteria in sterile microreaction tubes were mixed with 100 l PBS or 100 l PBS ϩ Cm (70 g/ml for K. pneumoniae, 50 g/ml for E. coli, 250 g/ml for S. aureus) and incubated at 37°C using an overhead rotator. Samples were drawn after 30, 60, 90, and 180 min, and surviving CFU were quantified by plating serial dilutions.
Wound fluid mediated killing
E. coli was grown overnight in THB and washed two times in PBS. Bacteria were incubated at 1 ϫ 10 6 CFU/ml in RPMI-THB ϩ wound fluid ϩ 5 g/ml Cm in 200 l in 96-well plates. CFU were determined as described above.
Murine wound infection model
Both flanks of 11-12 wk old female BALB/C mice (Jackson Laboratories, West Grove, PA, USA) were shaved and treated with Nair. Three days later mice were anesthetized with 75 mg/kg ketamine, 8 mg/kg xylazine, 1.5 mg/kg acepromazine intraperitoneally, and a 0.5-cm incision was made on each flank by scalpel. Twenty hours after being wounded, mice were reanesthetized, flanks were disinfected with 70% alcohol, and wounds were reopened by scalpel. One wound was infected with 5 l of RPMI 1640 ϩ 10 7 CFU of E. coli and the other wound with 5 l RPMI 1640 ϩ 10 7 CFU of E. coli ϩ 10 g/ml Cm. One hour after infection wounds and surrounding tissue were excised, placed in 500 l ice-cold PBS, and weighed, and 500 l PBS containing 1 mg/ml cytodex glass beads (Sigma-Aldrich) were added to the samples. The samples were vigorously vortexed for 5 min, and CFU was enumerated as described above.
Statistics
Experimental differences in the in vitro assays were evaluated by unpaired Student's t test; results of the mouse challenge studies were evaluated by paired Student's t test. 
Assurances
All animal experiments were approved by the UCSD Committee on the Use and Care of Animals and performed using accepted veterinary standards. Experimentation using human blood was approved by the UCSD Human Research Protection Program.
RESULTS
Bacteriostatic antibiotics can inhibit AMP killing
The Gram-negative bacterium Escherichia coli was exposed to varying doses of synthetic human LL-37 in the presence or absence of antibiotics. An unexpected result was observed in studies with the broad-spectrum, primarily bacteriostatic antibiotic Cm. As LL-37 concentration was increased into the bactericidal range against E. coli, significantly less bacterial killing was observed in the presence of 15 M Cm than with no antibiotic at all (Fig. 1A) . With the use of a fixed bactericidal concentration of 10 M LL-37, an antibiotic dose-response curve pinpointed the abrupt onset of antagonism to the concentration where Cm began to exert bacteriostatic activity (Ն15 M; Fig. 1B ). To expand on these observations, kinetic killing curves for synthetic murine mCRAMP against E. coli or the Gram-positive bacterium S. aureus were performed in the presence or absence of bacteriostatic concentrations of either Cm or the commonly prescribed macrolide antibiotic Em. Em-induced bacteriostasis significantly impaired murine cathelicidin (mCRAMP) killing of E. coli and S. aureus (Fig. 1C, D) ; similar effects on mCRAMP killing of E. coli and S. aureus were observed with Cm-induced bacteriostasis (not shown). AMP antagonism was not limited to the ribosomal protein synthesis inhibitors Em and Cm, since mCRAMP killing of E. coli was blocked after bacteriostasis induced by TMP/SFX, a commonly prescribed broad-spectrum antibiotic that targets the folate biosynthetic pathway (Fig. 1E) .
Killing kinetics of mCRAMP against a urinary tract isolate of Klebsiella pneumoniae were inhibited by bacteriostatic concentrations of Cm or Em ( Fig. 2A, B) , and human LL-37 killing of an EHEC disease isolate was delayed in the presence of Cm (Fig. 2C) . In the E. coli studies, even if addition of bacteriostatic Cm was delayed for 30 min after initiation of mCRAMP killing, a significant rescue of bacterial survival was seen (Fig.  2D) . The inhibitory effect of bacteriostatic antibiotics on AMP killing was not restricted to cathelicidins, as addition of Cm or Em impaired the killing of E. coli, K. pneumoniae, and S. aureus by piscidin (aka moronecidin), a cationic AMP of nonmammalian origin (5, 8;  Fig. 3 ).
Antibiotic antagonism of AMP action requires effective bacteriostasis
To further examine the association of antibiotic-induced bacteriostasis with AMP antagonism, the E. coli test isolate was passed several times in gradually increasing concentrations of Cm to induce stepwise resistance to the antibiotic. We found that the Cm-resistant isolate of E. coli became fully susceptible to mCRAMP in the presence of Cm, i.e., the inhibitory effect of Cm was dependent on effective bacteriostasis (Fig. 4A) . Similar findings were observed with an Em-resistant S. aureus transposon mutant, as addition of Em did not affect mCRAMP activity; however, AMP killing of the same bacterial strain was strongly impeded by bacteriostatic Cm (Fig. 4B) . Likewise, when S. aureus was transformed with a plasmid containing an Em-resistance gene, susceptibility to mCRAMP in the presence of Em was restored (Fig. 4C) . Taken together, these experiments indicate that the antagonistic effects of Cm and Em do not involve direct interaction with the cathelicidin peptide; rather, the two bacteriostatic pharmaceutical antibiotics act to decrease bacterial susceptibility to AMP killing.
Cm-induced transmembrane potential shifts in S. aureus
A study by Koo et al. (9) demonstrated that the bactericidal activity of platelet microbicidal proteins is in part dependent on the transmembrane potential of S. aureus. Induced bacteriostasis of S. aureus using 77 M Cm led to a measurable depolarization within 30 min when compared with control cells (Fig. 5A) . This treatment did not alter PI uptake, indicating that Cm-induced bacteriostasis did not alter S. aureus membrane permeability or viability. The potassium ionophor valinomycin produced hyperpolarization of both Cm-treated and untreated cells. Protection of S. aureus from mCRAMP killing by Cm-induced bacteriostasis was observed even after hyperpolarization of the target cell membrane (Fig. 5B) .
Human AMP LL-37 binds preferentially to dividing bacteria
Cathelicidins kill bacteria by assembly in the cell membrane of the target microorganism to form pores or otherwise damage its functional integrity (10, 11, 12) . Confocal microscopy was used to examine the interaction of rhodamine-labeled human LL-37 with E. coli in the presence or absence of bacteriostatic concentrations of Cm (fluorescently labeled LL-37 retains anti- Fig. 6A, B) . Control experiments demonstrated that LL-37 bound to heatkilled E. coli equivalently in the presence or absence of Cm (Fig. 6C, D) , ruling out a direct interference of Cm with the labeled AMP. Examination of LL-37-treated E. coli cultures in the absence of antibiotics demonstrated preferential targeting of dividing bacteria over nondividing bacteria, with maximal staining at the plane of cell division (Fig. 6E, F) . These results suggest that during cell division, the bacterial enters a phase of heightened vulnerability to AMP killing. Consequently, the antagonistic effect of bacteriostatic antibiotics on AMP killing may derive from preventing bacteria from entering this condition of heightened susceptibility.
Bacteriostatic antibiotics can impair complementdependent serum killing of bacteria
Another important component of innate immunity that targets bacterial cell membranes to kill via pore formation is the C5-C9 membrane attack complex of complement generated after activation of the classical, mannose-binding lectin or alternative pathways in mammalian sera. While E. coli was rapidly cleared in human sera in a C9-dependent fashion, the addition of bacteriostatic Cm significantly decelerated the rate of bacterial killing (Fig. 7A) . Bacteriostatic Cm also exerted an inhibitory effect on serum killing of K. pneumoniae (Fig. 7B) . Similar to our observations in cathelicidin killing, the antagonistic effect of bacterostatic Cm on serum killing was due to an effect on the bacteria rather than an interaction with complement factors. The antagonistic effect of Cm on serum killing was absent when a Cm-resistant E. coli strain was tested (Fig. 7C) , and complement consumption by heat-killed E. coli was unaffected by Cm (Fig. 7D) .
Bacteriostatic antibiotics can impair bacterial killing in whole blood and wound fluid
We next examined whether the phenomenon of bacteriostatic antibiotic interference with innate immune killing mechanisms could be extrapolated to mammalian tissue fluids, which use both AMPs and complement to combat bacterial pathogens. As seen in Fig.  8A-C, E. coli, K. pneumoniae, and an AMP-susceptible S. aureus strain (6) were killed significantly more slowly in freshly isolated human whole blood when bacteriostatic concentrations of Cm were added. A similar antagonistic effect of bacteriostatic Cm on killing of E. coli in human wound fluid was observed (Fig. 8D) . Finally, we challenged mice with equivalent quantities of untreated and Cm-inhibited E. coli in a model of acute wound infection. Paradoxically, 1 h after challenge, antibiotic-treated bacteria had enhanced survival in the mouse wound environment when compared to the untreated bacteria (Fig. 8E) .
DISCUSSION
Our studies demonstrate that bacteria, upon growth suppression by bacteriostatic antibiotics, can become more resistant to mammalian AMPs and complement in vitro and to innate immune clearance in specific host biological fluid and tissue environments ex vivo and in vivo. The effects of antibiotic suppression on bacterial interaction with membrane-active host defense molecules also provide new perspective and context to observations from earlier literature, including the findings that maximal susceptibility of S. aureus to thrombin-induced microbicidal protein (tPMP) or Bordetella pertussis to complement occurred during exponential growth phase (11, 14) or the observation that neutrophil defensin activity against S. aureus was enhanced by cell-wall active antibiotics, while potentially impeded by ribosomally active agents (15) . Antibiotics or combinations of antibiotics with bactericidal activity are often touted as superior to bacteriostatic regimens in complicated infections of bones, heart valves, or the central nervous system (16, 17) . Further, because a killed microorganism cannot mutate, the choice of bactericidal over bacteriostatic therapies is proposed to curtail development of antibiotic resistance (18) . Our discovery that bacteriostatic antibiotics can impair AMP or complement function suggests that certain pharmaceutical therapies could allow bacteria to persist longer in host tissue environments where innate immune responses are normally summoned. The resultant opportunity for adaptation to such environments could in theory enhance bacterial virulence.
Our observation that cathelicidin peptide preferentially targets replicating bacteria at the plane of cell division likely provides a mechanistic clue to the observed phenomenon of bacteriostatic antibiotic antag- onism of AMP action. The observation that bacteriostasis can be achieved not only by two different protein synthesis inhibiting antibiotics (Cm and Em) but also the folate biosynthesis inhibitor TMP/SX suggests that the bacteriostasis per se is contributing to AMP resistance rather than the decreased synthesis of a target protein molecule. Since the microbicidal actions of cationic molecules such as nisin or insect defensins have been shown to require a threshold electrical potential across the target membrane (19, 20) , it is possible that bacteriostatic Cm-induced protection of S. aureus from mCRAMP-mediated killing might in part be related to the detectable membrane depolarization. However, when we hyperpolarized the S. aureus membane with valinomycin such that the electrical potential after Cm-treatment was similar to untreated cells, significant protection against AMP-mediated killing was still observed.
Small colony variants (SCV) of S. aureus area naturally occurring subpopulation with slow growth and other abnormal phenotypic characteristics that can emerge in chronic and persistent infection and on exposure to specific antibiotics (21, 22) . We did not observe any such variants during the course of our experiments, but it is interesting to note that parallels may be drawn in the larger scheme, since cell wall-active pharmaceutical antibiotics are less effective against SCV and this diminished activity could theoretically in be related to decreased growth and fewer period of vulnerability during cell division.
Pharmaceutical antibiotics are often tested in combination against pathogenic microbes to probe for synergistic or antagonistic interactions. For example, Cm may be synergistic with the cell-wall active antibiotic ampicillin against bacteria for which Cm is bactericidal but antagonistic to ampicillin against bacteria for which Cm is bacteriostatic (23) . Our current findings suggest that similar attention should be paid to the interaction of bacteriostatic antibiotics with key effector molecules of our innate immunity. 
